Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: A population-based study

Journal of Hypertension

Volumn 25, Issue 3, 2007, Pages 689-697

  Van Wijk, Boris L G ^a   Avorn, Jerry ^b   Solomon, Daniel H ^b   Klungel, Olaf H ^a   Heerdink, Eibert R ^a   De Boer, Anthonius ^a   Brookhart, Alan M ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adherence; Blood pressure lowering drugs; Discontinuation; Hypertension; Persistence; Restarting

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIASTHMATIC AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; DATA BASE; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK;

EID: 33846813606     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280148a58     Document Type: Article

References (40)

1. Ezzati M, Vander Hoorn S, Lawes CM, Leach R, James WP, Lopez AD, et al. Rethinking the 'diseases of affluence' paradigm: global patterns of nutritional risks in relation to economic development. PLoS Med 2005; 2:E133.
2. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534-2544.
3. Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens 2004; 18:545-551.
4. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10-17.
5. Stephenson J. Noncompliance may cause half of antihypertensive drug 'failures'. JAMA 1999; 282:313-314.
6. Burnier M, Schneider MP, Chiolero A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19:335-341.
7. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, Dobkin PL. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98:1535-1544.
8. Gerth WC. Compliance and persistence with newer antihypertensive agents. Curr Hypertens Rep 2002; 4:424-433.
9. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23:2101-2107.
10. Bourgault C, Rainville B, Suissa S. Antihypertensive drug therapy in Saskatchewan: patterns of use and determinants in hypertension. Arch Intern Med 2001; 161:1873-1879.
11. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005; 19:607-613.
12. Brookhart AM, Katz JN, Finkelstein JS, Arnold M, Polinski J, Patrick AR, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of non-compliance. Am J Med 2007; in press.
13. PHARMO. PHARMO Records Linkage System, 2006. Available at: http://www.pharmo.nl/ [accessed 27 May 2006].
14. Herings RM, Bakker A, Stricker BH, Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Commun Health 1992; 46:136-140.
15. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan vs. other artihypertensive drug classes. Clin Ther 2001; 23:1999-2010.
16. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998; 20:764-771.
17. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006; 166:332-337.
18. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004; 19:638-645.
19. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133:144-153.
20. Centraal Bureau voor de Statistiek. Statistisch Jaarboek 2004. Voorburg/Heerlen: Centraal Bureau voor de Statistiek; 2004.
21. Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37:846-857.
22. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50:619-625.
23. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497.
24. Cardinal H, Monfared AA, Dorais M, LeLorier J. A comparison between persistence to therapy in ALLHAT and in everyday clinical practice: a generalizability issue. Can J Cardiol 2004; 20:417-421.
25. Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA 1990; 263:1653-1657.
26. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006; 59:11-17.
27. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165:1147-1152.
28. DiMatteo MR, Sherbourne CD, Hays RD, Ordway L, Kravitz RL, McGlynn EA, et al. Physicians' characteristics influence patients' adherence to medical treatment: results from the Medical Outcomes Study. Health Psychol 1993; 12:93-102.
29. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63:892-909.
30. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 2006; 24:1193-1200.
31. Gregoire JP, Moisan J, Guibert R, Ciampi A, Milot A, Gaudet M, Cote I. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002; 55:728-735.
32. Salvetti A, Ghiadoni L. Thiazide diuretics in the treatment of hypertension: an update. J Am Soc Nephrol 2006; 17 (Suppl 2):S25-S29.
33. Opie LH, Messerli FH. The choice of first-line therapy: rationale for low-dose combinations of an angiotensin converting enzyme inhibitor and a diuretic. J Hypertens 2001; 19 (Suppl):S17-S21.
34. Struijker-Boudier HA. The right drug and the right dose. J Hypertens 2003; 21(Suppl):S31-S36.
35. Okuno J, Yanagi H, Tomura S. Is cognitive impairment a risk factor for poor compliance among Japanese elderly in the community? Eur J Clin Pharmacol 2001; 57:589-594.
36. van Servellen G, Chang B, Garcia L, Lombardi E. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS 2002; 16:269-281.
37. Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, et al. Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004; 45:394-402.
38. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004; 27:117-124.
39. Wang PS, Bohn RL, Knight E, Glynn RJ, Mogun H, Avorn J. Noncompliance with antihypertensive medications: the impact of depressive symptoms and psychosocial factors. J Gen Intern Med 2002; 17:504-511.
40. Lancaster T, Hajek P, Stead LF, West R, Jarvis MJ. Prevention of relapse after quitting smoking: a systematic review of trials. Arch Intern Med 2006; 166:828-835.